Brief reports
Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion

https://doi.org/10.1016/j.amjcard.2003.12.009Get rights and content

Abstract

To test the hypothesis that a statin could reduce the recurrence rate of atrial fibrillation after electrical cardioversion (EC), we performed an open, controlled multicenter study. Patients (n = 114) who had atrial fibrillation >48 hours and who were scheduled for EC were randomized to receive 40 mg of pravastatin once daily for 3 weeks before and 6 weeks after EC or no drug in addition to standard therapy. Pravastatin did not reduce the recurrence rate of atrial fibrillation after EC.

References (12)

There are more references available in the full text version of this article.

Cited by (0)

This study was supported by Bristol-Myers Squibb Norway Ltd., Oslo, Norway, whose support covered all costs of the study medication.

View full text